Peter M. Haverty
Papers
1
Total Citations
114
H-Index
1
About
Peter M. Haverty is a distinguished researcher whose work sits at the intersection of cancer biology, chemical proteomics, and therapeutic discovery. His most influential contributions center on the KEAP1/Nrf2 pathway, a critical cellular defense mechanism against oxidative stress that is frequently hijacked in cancers such as non-small cell lung cancer. In his landmark 2015 study, cited over 110 times, Haverty employed advanced mass spectrometry profiling to reveal that brusatol, a natural compound, acts as a potent inhibitor of global protein synthesis—not as a direct Nrf2 inhibitor, as previously assumed. This finding reshaped the understanding of brusatol’s mechanism and opened new avenues for targeting Nrf2-addicted tumors. Beyond this, Haverty’s work exemplifies the power of integrating proteomics with functional genomics to uncover unanticipated drug actions. His research has had a lasting impact on the field, guiding efforts to develop more precise therapies for cancers driven by oxidative stress pathways. For students and researchers, Haverty’s career is a compelling model of how rigorous, hypothesis-driven science can challenge established dogma and drive translational progress.
Research Focus
Key Achievements
Top Papers
- 1